中国健康受试者单次和多次口服Obicetrapib片的药代动力学、药效学和安全性的随机、平行分组、开放、单中心I期临床试验。
[Translation] A randomized, parallel-group, open-label, single-center phase I clinical trial to investigate the pharmacokinetics, pharmacodynamics, and safety of single and multiple oral administration of Obicetrapib tablets in healthy Chinese subjects.
主要目的:
评价中国健康受试者单次和多次口服Obicetrapib后的PK特征。
次要目的:
评价中国健康受试者单次和多次口服Obicetrapib后的PD特征,探索药物的剂量-暴露-效应关系;
评价中国健康受试者单次和多次口服Obicetrapib后的安全性。
[Translation] Primary purpose:
To evaluate the PK characteristics of Obicetrapib after single and multiple oral administration in healthy Chinese subjects.
Secondary purpose:
To evaluate the PD characteristics of Obicetrapib after single and multiple oral administration in healthy Chinese subjects, and to explore the dose-exposure-effect relationship of the drug;
To evaluate the safety of Obicetrapib after single and multiple oral administration in healthy Chinese subjects.
100 Clinical Results associated with Nanjing CR Medicon Pharmaceutical Technology Co., Ltd.
0 Patents (Medical) associated with Nanjing CR Medicon Pharmaceutical Technology Co., Ltd.
100 Deals associated with Nanjing CR Medicon Pharmaceutical Technology Co., Ltd.
100 Translational Medicine associated with Nanjing CR Medicon Pharmaceutical Technology Co., Ltd.